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Abstract: N-containing quaternary stereocenters represent 
important motifs in medicinal chemistry. However, due to their 
inherently sterically hindered nature, they remain underrepresented 
in small molecule screening collections. As such, the development of 
synthetic routes to generate small molecules that incorporate this 
particular feature are highly desirable. Herein, we describe the 
diversity-oriented synthesis (DOS) of a diverse collection of 
structurally distinct small molecules featuring this three-dimensional 
(3D) motif. The subsequent derivatisation and the stereoselective 
synthesis exemplified the versatility of this strategy for drug 
discovery and library enrichment. Chemoinformatic analysis 
revealed the enhanced sp3 character of the target library and 
demonstrated that it represents an attractive collection of biologically 
diverse small molecules with high scaffold diversity. 
Introduction 
N-containing quaternary stereocenters are important motifs in 
medicinal chemistry and are present in significant essential 
medicines including the antihypertensive methyldopa 
(Aldomet®) and the anaesthetic ketamine (Ketalar®) (Figure 1, 
a-b).[1] The presence of this particular stereocenter in the three 
small molecules currently under clinical evaluation, Ranirestat,[2] 
Veliparib[3] and Verubecestat[4]  (Figure 1, c-e), further highlight 
its relevance in drug discovery contexts. The biological activity of 
such compounds has been generally shown to be intrinsically 
related to their absolute configuration.[5–10] For instance, 
investigations have concluded that the presence of a N-
containing quaternary (R)-stereocenter within the core structure 
is necessary for interaction of the substituents with the pockets 
of the β-secretase (BACE1) binding site.[9],[10] Moreover, the 
presence of such restricted elements within a small molecule 
can provide conformational restrictions owing to their sterically 
hindered nature, thereby increasing the molecular complexity of 
a given molecule, which has been shown to be desirable 
chemical feature for bioactive molecules.[11],[12] 
Figure 1. Examples of bioactive compounds containing a N-substituted 
quaternary carbon.  
Studies have shown that increased complexity (e.g. sp3-rich 
cycles or quaternary carbons) can correlate to an increase in the 
selectivity, potency and metabolic stability of drug candidates, 
along with the successful progression from clinical stages to 
drug approval.[13],[14] However, due to their congested nature, the 
incorporation of N-containing quaternary stereocenters into 
small molecules poses a synthetic challenge for organic 
chemists.[15–19] As a result, small molecules bearing this 
particular feature are still under-represented in probe and drug 
discovery screening collections. 
 From a synthetic perspective, despite all the advances 
made in the field of asymmetric catalysis to generate α-branched 
amino-containing compounds,[16–19] the majority of the reported 
reactions are based on simple scaffolds with restricted structural 
diversity and there has been a limited exploration into the 
construction of such motifs into more complex molecules. It has, 
however, been demonstrated that the use of α,α-disubstituted 
amino esters as subunits to prepare complex molecules bearing 
this sterically hindered motif can be particularly effective. Thus, 
some examples in the literature have validated this strategy by 
the target-oriented synthesis (TOS) of biologically active small 
molecules.[20] More recently, allyl-containing cyclic quaternary 
amino esters have also been used for the diversity-oriented 
synthesis (DOS) of small molecule collections.[21],[22] However, 
structurally diverse, sp3-rich and complex libraries are still under-
represented in probe and drug discovery screening collections. 
In addition to these deficiencies, within the literature, 
significant synthetic challenges have been identified in relation 
to the development of chemistries which tolerate polar 
functionalities such as amines, N-heterocycles and unprotected 
polar groups.[23] Moreover, within a fragment-based drug 
discovery context, there have been recent calls for the design 
and synthesis of novel compounds that feature multiple 3D 
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growth vectors whilst incorporating polar functionality for 
molecular recognition.[24] In response to this, notable examples 
of efficient syntheses of diverse sp3-rich libraries have been 
recently published[25–32], however there is still an outstanding 
need for diverse libraries featuring this key N-containing 
quaternary stereocenter motif. 
With these points in mind, we envisioned that α,α- 
disubstituted propargyl amino esters could act as a versatile and 
pluripotent platform for the DOS of structurally diverse screening 
collection featuring a stereogenic N-containing quaternary 
carbon (Figure 2). In this manner, the reactivity of its three 
functional vectors, namely the terminal alkyne, the amine as well 
and the ester moieties could be exploited in both inter- and 
intramolecular reactions.[33]  
Figure 2. Synthetic versatility of α,α-disubstituted amino esters for the DOS of 
N-substituted quaternary carbon containing small molecules. 
Results and discussion 
Synthesis of the DOS library 
To validate our hypothesis, we initially selected the racemic -
methyl propargylglycine 1 (R = Me) as a model substrate to 
perform the reagent-based DOS outlined in this work (Scheme 
1). Our investigations began via alkylation of the amino group in 
1 through the introduction of a tert-butyl carbamate, propargyl, 2-
azido benzoyl or an acyl group to generate the first set of highly 
functionalised intermediates (S2-6, for all intermediates see 
Scheme S1). Subsequent pairing of the functionalities present in 
these intermediates with the terminal alkyne could be achieved 
through different metal-catalysed cyclisations (Scheme 1, steps 
a/f). Accordingly, Co-induced [2+2+2] cyclotrimerisation afforded 
2 and 3, whilst hydroamination using gold catalysis yielded 4 
and 6. Finally, intramolecular Ru-mediated click chemistry gave 
rise to compound 5.  
In a similar fashion, Ru-mediated 1,5-click chemistry could 
be used to generate acyclic compounds 7 and 8, through 
intermolecular reaction of a protected form of 1 with the 
commercially available chloro-oxime or the corresponding azido 
ester. In turn, lactamisation of the ester moieties within 7 and 8 
with the quaternary amine (Scheme 1, step e/f) afforded the 
rigidified scaffolds 9 and 10. Further exploitation of the terminal 
alkyne handle within 1 via Ru- or Cu- catalysis afforded the 
acyclic 1,5- and 1,4-phenyl substituted triazoles 11 and 12, 
respectively. Finally, Sonogashira cross-coupling of the terminal 
alkyne followed by hydrogenation afforded 13 (Scheme 1, step 
e). 
Next, an exploration into intramolecular cyclisations between 
the ester functionality within 1 and the terminal alkyne was 
undertaken (Scheme 1, step c/d). Reduction of the carboxylic 
moiety into the corresponding alcohol provided the opportunity 
to introduce additional unsaturated moieties through the 
alkylation of the newly generated hydroxyl group to afford the 
allylic- and propargylic intermediates. Following this, metal- 
catalysed intramolecular cyclisations such as Co-induced 
[2+2+2] cyclotrimerisations - when starting from the dialkyne 
intermediate - or a sequence of ring-closing eynyne metathesis 
followed by Diels-Alder cycloaddition – when starting from the 
allylic intermediate – afforded novel bi- and tricyclic oxepine-
containing scaffolds 14, 15 and 16. Additionally, ester hydrolysis 
of 1 to the carboxylic acid followed by the Cu-promoted 
intramolecular cyclisation afforded 17, whilst Ru-mediated 
cyclisation of the amino alcohol intermediate with the terminal 
alkyne generated 18.  
Smaller propargyl-containing fragments featuring different 
polar functionalities could also be synthesised via pairing the 
amino and ester moieties within 1. Pyrrole 19 was prepared via 
Paal-Knorr reaction and a nitrile-based secondary branch point 
was introduced to afford 20 (Scheme 1, step a, see SI). 
Benzodiazepine 21 was prepared starting from the azido 
benzoyl intermediate followed by azide reduction to facilitate the 
lactamisation reaction with the ester functionality (Scheme 1, 
steps a/b). Again, acylation of 1 proved useful in generating 
acyclic intermediates which could in turn be cyclized with the 
ester functionality. For example, Dieckmann condensation of the 
malonyl derivative followed by decarboxylation, yielded the 
substituted pyrrolidone 22. Reduction of the ester to a hydroxyl 
again provided the opportunity to cyclise between this moiety 
and the amino group (Scheme 1, steps c/b). In this manner, 
using a single N-Boc protected amino alcohol, aziridine 23 and 
oxazolidinone 26 could be both synthesized. Finally, two further 
propargyl-containing scaffolds were synthesized by N-acylation 
followed by hydroxyl-mediated cyclisation or vice versa, O-
acylation followed by nitrogen-mediated cyclisation, to yield 
morpholinones 24 and 25, respectively.  
The reactivity of both 19 and 20 could be further exploited to 
generate five different scaffolds in a synthetically efficient 
manner. Unexpectedly, when extending the reaction time for the 
formation of 19, an alternative intramolecular cyclisation was 
observed between the terminal alkyne and the in situ hydrolysed 
methyl ester, giving rise to 27. Moreover, gold catalysis 
promoted the intramolecular cyclisation between the terminal 
alkyne and a pyrrole within 19 to afford dihydroindolizine 28. We 
next sought to explore the reactivity of cyano functionality within 
20. A novel one-step approach to synthesise tricyclic pyrrole-
containing scaffolds was developed via Co-catalysed [2+2+2] 
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Scheme 1. Synthesis of structurally diverse N-substituted quaternary carbon containing small molecules from α,α-disubstituted amino ester 1: a) amine 
derivatisation; b) pairing of the amino and ester moieties; c) ester derivatisation; d) pairing of the alkyne and ester moieties; e) alkyne derivatisations; f) pairing of 
the amino and alkyne moieties. For reaction conditions see Supporting Information. 
cyclotrimerization. Thus, starting from 20 CpCo(CO)2 and 
cyclopropylacetylene could be utilised to furnish fused 
heterocycles 29 and 30. Further scaffold exploration using this 
approach is currently being investigated in our research group. 
Finally, Pd-catalysed reduction of the nitrile moiety within 20, 
allowed the intramolecular cyclisation affording the propyl- 
substituted pyrrolopiperazine 31.  
Finally, the terminal alkyne within 25 and 26 could be further 
modified to generate two conformationally restricted small 
molecules 32 and 33 via vinyl iodide formation followed by 
Buchwald coupling.[34]  
To demonstrate the synthetic potential of the propargyl-
containing warheads for library enumeration, the alkyne handle 
within 19, 21-23 and 26 was further modified (Figure 3, A). Thus, 
Cu-catalysed click reaction gave the 1,4-substituted triazoles 
19a, 21a, 22a, and 26a; Sonogashira cross-coupling afforded 
21b and 22b; hydrogenation of the alkyne produced saturated 
derivatives 21c and 22c and, finally, Ru-mediated click reaction 
afforded the 1,5- triazole 23d.  
Using the strategy outlined above we synthesised a 
structurally diverse library of 40 compounds based around 27 
molecular frameworks relevant for drug discovery (see Figure 
S1) featuring a N-containing quaternary stereocenter. Each 
compound was obtained in no more than five synthetic steps  
(with an average of only three steps) starting from 1, which 
demonstrates the efficiency of this process. Importantly, the 
flexibility of this methodology was further exemplified via the 
synthesis of the phenyl-derivative 10’ (Figure 3, B). The ability to 
synthesise the asymmetric version of any compound from the 
library was also validated through the synthesis of the optically 
pure triazolodiazepine (R)-10 (Figure 3, C) from (R)-1 (see SI). 
Chemoinformatic assessment 
In order to assess the molecular shape distribution of the 
resulting library, a principal moments of inertia (PMI) analysis 
was conducted (Figure 4).[35] Pleasingly, analysis of the DOS 
library showed a broad distribution of molecular shape space, 
with 93% of the library out of ‘flatland’[36] and possessing  
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Figure 3. (A) Exemplification of the synthesis of other derivatives via alkyne modifications. Reaction conditions: 19a, 21a, 22a, 26a: azidobenzene, CuSO4·5H2O, 
t-BuOH:H2O, rt, 72-92%; 21b and 22b: PdCl2(PPh3)2, CuI, Et3N, benzyl 2-iodobenzoate, DMF, rt, 16h, 60% and 26%, respectively; 21c and 22c: Pd/C, H2, MeOH, 
rt, 2h, 69% and 87%, respectively; 23d: ethyl 2-azidoacetate, Cp*RuCl(COD), PhMe, rt - 60 ºC, 21h, 42% (B) Synthesis of the phenyl-containing derivative. 
Reaction conditions: i) Boc2O, THF, 70 ºC, o/n, 84%; ii) ethyl 2-azidoacetate, Cp*RuCl(COD), PhMe, 80 ºC, 1h, 87%; iii) TFA, CH2Cl2, 2h then NaHCO3, 
(quantitative yield); iv) PhMe, 150 ºC, o/n, 76%. (C) Synthesis of an enantiopure component of the library. Reaction conditions: i) Boc2O, THF, 70 ºC, o/n, 90%; ii) 
ethyl 2-azidoacetate, Cp*RuCl(COD), PhMe, 50 ºC, 1h, 76%; iii) TFA, CH2Cl2, 2h then NaHCO3, 93%; iv) PhMe, 150 ºC, o/n, 79%. 
considerable 3D character. In order to investigate the influence 
of the substituent at the quaternary center on the shape, a virtual 
collection based on the phenyl-derivatives (DOS Library Ph, see 
SI) was plotted in the same graph (Figure 4). Comparative 
analysis between the two DOS libraries highlighted a shift to the 
right-hand side of the plot and more 3D character when 
modifying the quaternary substituent. This data suggests that 
installation and substituent modification of the N-containing 
quaternary sp3 stereocenter represents a useful strategy for 
‘tuning’ the 3D molecular shape (and thus target binding profile) 
of a given molecule. Finally, the commercially available 
Maybridge ‘Rule of 3’ core fragment library comprising 1,000 
screening compounds (see SI and Figure 4) was analysed and 
compared to the DOS library. Importantly, only 28% of the 
Maybridge library appeared out of ‘flatland’ with a high 
proportion of ‘disk’ and ‘rod’ type compounds, which highlights 
the increased diversity and more 3D character displayed by the 
DOS library. Interestingly, only two compounds within the 
Maybridge collection featured a N-containing quaternary carbon, 
exemplifying the limited inclusion of this moiety within traditional 
screening collections.  
In addition to PMI analysis, calculation of the mean values 
for physicochemical properties related to the ‘Rule of three’ 
guidelines[37] commonly adopted within fragment library 
generation (Table 1) was conducted. Notably the DOS library 
featured a low mean SlogP (1.37), higher mean number of chiral 
centres (1.1) and low fraction of aromatic atoms per molecule 
(0.29), compared to commercial libraries (See SI), 
demonstrating the amenability of the DOS library to fragment-
based drug discovery approaches.[38]  
Whilst PMIs are a common way of assessing shape diversity, 
the relationship to bioactivity coverage appears to be more 
complex.[39] To assess the coverage of our DOS library in 
bioactivity space, we compared it to two previously reported 
focused synthetic libraries,[40],[41] as well as bioactive compounds 
retrieved from ChEMBL a database of binding and functional 
data for a large number of drug-like bioactive compounds. The 
molecular weight range of the bioactive compounds selected for 
the analysis was between 200 and 700, and the compounds 
covered different target classes.[42] Then, their Morgan 
fingerprints[43] were generated for  multi-dimensional scaling 
(MDS). Our DOS library (Figure 5, shown in black) covers a 
wider area of biologically relevant chemical space compared to 
the targeted libraries, overlapping with areas occupied by kinase 
inhibitors, ion channels blockers, membrane receptors ligands  
Figure 4. Comparative PMI plot analysis of DOS library (blue circles), 
Maybridge core 1000-member Ro3 Fragment library (green triangles) and the 
DOS Ph virtual library (red squares). Compounds within ‘flatland’ (represented 
by npr1 + npr2 value < 1.1, dashed line) could also be identified; the further 
from this area the molecules move the more they extend into three-
dimensional space.[36] 
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Table 1. Mean physicochemical properties of fragment collections 
Property [a] 
Ideal 
Range [b] 
This work 
Maybridge 
'Ro3' Core 
collection 
Chembridge 
SlogP 
0-3 
1.37 1.92 1.31 
MW 
<300 
237 182 222 
HBA 
<3 
2.63 1.83 1.81 
HBD 
<3 
0.78 1.01 1.04 
Chiral 
centres 
- 1.10 0.14 0.27 
Fraction Ar - 0.29 0.52 0.42 
 [a] MW = molecular weight, HBA = number of hydrogen bond acceptors, HBD 
= number of hydrogen bond donors. [b] Ideal range based on guidelines of 
Fragment ‘Rule of three‘[37]. Green = inside ideal range. Yellow = extreme of 
ideal range. 
and ligands of other protein classes. 
Currently, the DOS library is being screened via high-
throughput X-Ray crystallography methods in collaboration with 
the XChem fragment screening facility at the Diamond Light 
Source synchrotron. Hits against three different target classes 
including hydrolases, the TGF-beta family of growth factors, and 
peptidases have been successfully identified. Further biological 
results from these initial campaigns will be published in due 
course.  
Conclusions 
In summary, we have developed a new, efficient reagent-based 
DOS approach using α-methyl-α-propargyl amino esters to 
generate a library of 40 structurally diverse small molecules. 
Importantly, throughout this sp3-rich library we have installed a 
N-containing quaternary stereocenter, polar functionalities and 
N-based heterocycles, answering key calls from within the field. 
The resultant library also adheres to the fragment rule of three 
guidelines, highlighting the amenability to this method of 
screening. Furthermore, we have demonstrated the scope of our 
library through modifications to the alkyne-containing scaffolds, 
the synthesis of a phenyl-containing derivative and the 
asymmetric version of an analogue, all of which can be applied 
to library enumeration. Finally, cheminformatic analysis has 
shown a broad molecular shape distribution, the importance of 
the quaternary sp3 carbon in modifying the molecular shape and 
the increased diversity and 3D character of the library when 
compared to a commercial library. The analysis of the resulting 
bioactivity space coverage showcases that the target library 
represents an attractive screening collection of biologically 
diverse small molecules. 
Experimental Section  
General Remarks.  
All reagents and solvents were purchased from commercial 
sources and used without further purification unless otherwise 
stated. All the experiments were carried out under a nitrogen 
atmosphere unless otherwise stated. Melting points were 
measured using a Büchi B545 melting point apparatus and are 
uncorrected. Thin layer chromatography (TLC) was performed 
on precoated Merck silica gel GF254 plates. Flash column 
chromatography was performed on silica gel (230–400 mesh). 
1H NMR and 13C NMR were recorded on a Bruker Avance 500 
MHz instrument in CDCl3 and MeOD. HRMS was recorded on a 
Micromass Q-TOF mass spectrometer or a Waters LCT Premier 
Time of Flight mass spectrometer. 
Methyl 3-methyl-7-phenyl-1,2,3,4-tetrahydro-2,6-
naphthyridine-3-carboxylate (2) and methyl 3-methyl-6-
phenyl-1,2,3,4-tetrahydro-2,7-naphthyridine-3-carboxylate 
(3): A solution of methyl 2-((tert-butoxycarbonyl)amino)-2-
methylpent-4-ynoate (S2) (150 mg, 0.62 mmol) in DMF (3.0 mL) 
was added to a suspension of sodium hydride (60% in mineral 
oil, 30 mg, 0.74 mmol) in DMF(3.2 mL) cooled to 0 ºC. After 10 
minutes stirring, propargyl bromide (80 wt. % in toluene, 0.138 
 
 
 
 
 
Figure 5. Bioactive space coverage of 
the DOS library, compared to two 
targeted compound libraries and seven 
different bioactivity classes of common 
protein targets obtained from ChEMBL 
(based on Morgan fingerprints and 
Multi-Dimensional Scaling, MDS; 
ellipses cover 90% of the data in each 
class. It can be seen that the DOS 
library displays significantly wider 
coverage in bioactivity space than the 
two targeted libraries, covering all 
common classes of drug targets used 
for comparison 
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minutes stirring, propargyl bromide (80 wt. % in toluene, 0.138 
mL, 1.24 mmol) was added and the mixture was warmed to 
room temperature and stirred for 4 hours. Then, the mixture was 
diluted with saturated aqueous solution of NH4Cl and the  
aqueous layer was extracted with EtOAc (3x). The combined 
organic layers were washed with brine, dried with Na2SO4, 
filtered, and the solvents were evaporated. The crude product 
was purified by flash column chromatography (silica gel 
petroleum ether/EtOAc, 5:1) to yield 168 mg of methyl 2-((tert-
butoxycarbonyl)(prop-2-yn-1-yl)amino)-2-methylpent-4-ynoate 
(S3) (97% yield) as a colourless oil. Rf = 0.40 (petroleum 
ether/EtOAc; 5:1); 1H NMR (400 MHz, CDCl3) δ 1.43 (s, 9H), 
1.70 (s, 3H), 1.99 (t, J = 2.6 Hz, 1H), 2.20 (t, J = 2.4 Hz, 1H), 
2.73 (dd, J = 17.1, 2.5 Hz, 1H), 3.12 (d, J = 16.6 Hz, 1H), 3.69 
(s, 3H), 4.02 (d, J = 18.5 Hz, 1H), 4.26 (br s, 1H); 13C NMR (101 
MHz, CDCl3) δ 22.0, 27.0, 28.3, 34.1, 52.4, 62.5, 70.9, 71.1, 
80.1, 80.9, 81.7, 154.3, 174.0; HRMS (ESI): m/z calcd for 
C15H22NO4 [M+H]+: 280.1543; found: 280.1534. 
CpCo(CO)2 (6.4 mg, 0.036 mmol) and benzonitrile (0.05 mL, 
0.48 mmol) were added to a solution of S3 (68 mg, 0.24 mmol) 
in toluene (2.4 mL), previously degassed with argon for 15 
minutes, and the mixture was heated at 110 ºC for 36 hours. 
Then, the solvent was removed under reduced pressure and the 
crude product was purified by column chromatography (silica 
gel; petroleum ether/EtOAc, gradient from 5:1 to 3:2). The 
resulting inseparable mixture of regioisomers (ca. 40:60 ratio as 
determined by 1H NMR) was dissolved in CH2Cl2 (1 mL) and 
TFA (0.5 mL) was then added to the solution. After 1 hour 
stirring the solvent was removed under reduced pressure. The 
crude product was dissolved in EtOAc (5 mL) and a saturated 
aqueous solution of NaHCO3 (5 mL) was added and the mixture 
was stirred for 10 minutes. Then, the organic layer was 
separated, dried over Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified by flash column 
chromatography (silica gel; gradient from EtOAc:MeOH 1:0 to 
9:1) to afford 20 mg of 2 (30% yield) and 18 mg of 3 (26% yield) 
both as a colourless oils. 
Data of minor regioisomer (2): Rf = 0.21 (EtOAc): 1H NMR (400 
MHz, CDCl3) δ 1.48 (s, 3H), 2.37 (br s, 1H), 2.83 (d, J = 16.7 Hz, 
1H), 3.35 (d, J = 16.7 Hz, 1H), 3.69 (s, 3H), 4.05 – 4.18 (m, 2H), 
7.39 (ddd, J = 7.3, 3.7, 1.3 Hz, 1H), 7.41 – 7.49 (m, 3H), 7.90 – 
7.98 (m, 2H), 8.37 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 26.6, 
37.3, 42.6, 52.5, 57.9, 120.6, 126.9, 128.3, 128.8, 128.8, 139.4, 
143.2, 147.8, 155.3, 175.9; HRMS (ESI): m/z calcd for 
C17H19N2O2 [M+H]+: 283.1441; found: 283.1431 
Data of major regioisomer (3): Rf = 0.32 (EtOAc): 1H NMR (400 
MHz, CDCl3) δ 1.48 (s, 3H), 2.03 (br s, 1H), 2.80 (d, J = 16.2 Hz, 
1H), 3.33 (d, J = 16.2 Hz, 1H), 3.68 (s, 3H), 4.08 (d, J = 17.0 Hz, 
1H), 4.19 (d, J = 17.1 Hz, 1H), 7.34 – 7.41 (m, 2H), 7.41 – 7.48 
(m, 2H), 7.86 – 7.97 (m, 2H), 8.43 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 26.4, 34.7, 44.7, 52.6, 58.1, 117.8, 126.9, 127.8, 
128.8, 129.0, 139.4, 143.3, 150.2, 155.1, 175.8; HRMS (ESI): 
m/z calcd for C17H19N2O2 [M+H]+: 283.1441; found: 283.1431. 
Methyl 2-methyl-2-(1H-pyrrol-1-yl)pent-4-ynoate (19): NaOAc 
(97 mg, 1.19 mmol) was added to a stirred solution of 1 (140 
mg, 0.99 mmol) in a mixture 5:3:1 of DCE:H2O:AcOH (2.24 mL) 
and the reaction was stirred at 90 ºC. After 5 minutes, 2,5-
dimethoxytetrahydrofuran (0.13 mL, 0.99 mmol) was added and 
the mixture was stirred at the same temperature overnight. 
Then, the reaction was cooled to room temperature, diluted with 
EtOAc and washed with saturated aqueous solution of NaCl. 
The organic layer was dried over Na2SO4, filtered and the 
solvents were concentrated in vacuo. The crude product was 
purified by flash column chromatography (silica gel; petroleum 
ether/EtOAc, 9:1) to yield 115 mg of 19 (61% yield) as a white 
solid. Rf = 0.28 (petroleum ether/EtOAc, 9:1); mp 55 – 57 ºC; 1H 
NMR (400 MHz, CDCl3) δ 1.94 (s, 3H), 2.05 (t, J = 2.6 Hz, 1H), 
3.00 (dd, J = 16.8, 2.6 Hz, 1H), 3.07 (dd, J = 16.8, 2.6 Hz, 1H), 
3.74 (s, 3H), 6.21 (t, J = 2.2 Hz, 2H), 6.83 (t, J = 2.2 Hz, 2H); 13C 
NMR (101 MHz, CDCl3) δ 22.8, 30.0, 53.1, 63.1, 72.3, 78.5, 
108.8, 118.7, 172.0; HRMS (ESI): m/z calcd for C11H14NO2 
[M+H]+: 192.1019; found: 192.1013. 
Methyl 2-(2-cyano-1H-pyrrol-1-yl)-2-methylpent-4-ynoate (20)  
Chlorosulfonyl isocyanate (0.047 mL, 0.55 mmol) was added 
drop-wise to a solution of 19 (70 mg, 0.37 mmol) in MeCN (3.6 
mL) at 0 ºC. After 1 hour stirring, DMF (0.14 mL, 1.85 mmol) was 
added and the mixture was stirred for 2 hours. Then, saturated 
aqueous solution of NaHCO3 was added and the reaction 
mixture was extracted with EtOAc (3x). The combined organic 
layers were dried over Na2SO4, filtered and the solvents were 
concentrated in vacuo. The crude product was purified by flash 
column chromatography (silica gel; petroleum ether/EtOAc, 4:1) 
to yield 57 mg of 20 (71% yield) as colourless oil. Rf = 0.29 
(petroleum ether/EtOAc; 5:1); mp 64 – 66 ºC;  1H NMR (400 
MHz, CDCl3) δ 1.88– 2.08 (m, 4H), 3.09 (dd, J = 17.5, 2.7 Hz, 
1H), 3.31 (dd, J = 17.5, 2.1 Hz, 1H), 3.84 (s, 3H), 6.19 (dd, J = 
3.8, 3.0 Hz, 1H), 6.93 (dd, J = 3.9, 1.5 Hz, 1H), 7.07 (dd, J = 2.8, 
1.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 23.8, 29.5, 53.7, 
64.5, 72.8, 77.2, 102.9, 108.5, 114.1, 123.2, 125.5, 171.5; 
HRMS (ESI): m/z calcd for C12H12N2NaO2 [M+Na]+: 239.0791; 
found: 239.0783. 
3-Methyl-5-methylene-3-(1H-pyrrol-1-yl)dihydrofuran-2(3H)-
one (27): NaOAc (26 mg, 0.32 mmol) was added to a stirred 
solution of 19 (30 mg, 0.16 mmol) in a mixture 5:3: of 
DCE:H2O:AcOH (1.6 mL) and the reaction was stirred at 90 ºC 
for 24 hours. Then, the reaction was cooled to room 
temperature, diluted with EtOAc and washed with saturated 
aqueous solution of NaCl. The organic layer was dried over 
Na2SO4, filtered and the solvents were concentrated in vacuo. 
The crude product was purified by flash column chromatography 
to yield 12 mg of 27 (42% yield) as a colourless oil. Rf = 0.22 
(petroleum ether/EtOAc, 9:1); 1H NMR (400 MHz, CDCl3) δ1.85 
(s, 3H), 3.11 (dt, J = 16.2, 1.5 Hz, 1H), 3.39 (dt, J = 16.2, 1.8 Hz, 
1H), 4.51 (dt, J = 3.2, 1.7 Hz, 1H), 4.91 (dt, J = 2.8, 2.1 Hz, 1H), 
6.24 (t, J = 2.2 Hz, 2H), 6.86 (t, J = 2.1 Hz, 2H); 13C NMR (101 
MHz, CDCl3) δ 24.2, 41.5, 61.6, 91.2, 109.7, 118.4, 151.3, 
173.5; HRMS (ESI): m/z calcd for C10H12NO2 [M+H]+: 178.0861; 
found: 178.0863. 
Methyl 5-methyl-5,6-dihydroindolizine-5-carboxylate (28): A 
solution of AuSPhos(MeCN)SbF6 (4.8 mg, 5 mol%) in DCE (0.1 
mL) was added drop-wise to a solution of 19 (21 mg, 0.11 mmol) 
and ethanol (0.032 mL, 0.55 mmol) in DCE (1.0 mL). The 
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resulting solution was heated for 2 hours at 40 ºC and then the 
solvent was removed under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel; 
petroleum ether /EtOAc, 4:1) to yield 17 mg of 28 (81% yield) as 
a colourless oil. Rf = 0.24 (petroleum ether/EtOAc, 5:1); 1H NMR 
(400 MHz, CDCl3) δ 1.80 (s, 3H), 2.49 (dt, J = 16.9, 2.7 Hz, 1H), 
2.95 (dd, J = 16.9, 6.1 Hz, 1H), 3.64 (s, 3H), 5.58 – 5.69 (m, 1H), 
6.12 (d, J = 2.5 Hz, 1H), 6.22 (t, J = 3.2 Hz, 1H), 6.46 (dd, J = 
9.7, 2.8 Hz, 1H), 6.85 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 
24.0, 35.8, 52.9, 61.3, 107.4, 108.9, 117.1, 118.9, 120.8, 130.3, 
174.0; HRMS (ESI): m/z calcd for C11H14NO2 [M+H]+: 192.1019; 
found: 192.1012. 
Methyl 2-cyclopropyl-6-methyl-5,6-dihydropyrrolo[1,2-
h][1,7]naphthyridine-6-carboxylate (29) and methyl 3-
cyclopropyl-6-methyl-5,6-dihydropyrrolo[1,2-
h][1,7]naphthyridine-6-carboxylate (30): CpCo(CO)2 (13.3 mg, 
0.038 mmol) and cyclopropylacetylene (0.048 mL, 0.57 mmol) 
were added to a solution of 20 (40 mg, 0.19 mmol) in toluene 
(3.5 mL), previously degassed with argon for 15 minutes, and 
the mixture was heated at 110 ºC for 36 hours. Then, the solvent 
was removed under reduced pressure and the crude product 
was purified by column chromatography (silica gel; gradient from 
petroleum/EtOAc, gradient from 4:1 to 2:1) to afford 14 mg of 29 
(27% yield) and 5 mg of 30 (10% yield) both as a white solids. 
Data of major regioisomer (29): Rf = 0.34 (petroleum 
ether/EtOAc; 4:1); mp 108 – 110 ºC; 1H NMR (400 MHz, CDCl3) 
δ 0.94 (dd, J = 8.2, 3.3 Hz, 2H), 0.99 – 1.12 (m, 2H), 1.88 (s, 
3H), 1.95 – 2.07 (m, 1H), 3.06 (d, J = 15.4 Hz, 1H), 3.43 (d, J = 
15.5 Hz, 1H), 3.54 (s, 3H), 6.33 (t, J = 3.2 Hz, 1H), 6.79 (d, J = 
7.8 Hz, 1H), 6.90 – 6.99 (m, 2H), 7.28 (d, J = 7.8 Hz, 1H); 13C 
NMR (101 MHz, CDCl3) δ 9.7, 17.2, 24.3, 39.4, 53.0, 61.2, 
107.9, 110.1, 117.8, 120.0, 120.2, 131.5, 135.1, 146.9, 161.7, 
173.1; HRMS (ESI): m/z calcd for C17H19N2O2 [M+H]+: 283.1441; 
found: 283.1435. 
Data of minor regioisomer (30): Rf = 0.23 (petroleum 
ether/EtOAc; 2:1); 1H NMR (400 MHz, CDCl3) δ 0.67 – 0.75 (m, 
2H), 0.97 – 1.03 (m, 2H), 1.82 – 1.92 (m, 4H), 3.08 (d, J = 15.5 
Hz, 1H), 3.43 (d, J = 15.5 Hz, 1H), 3.54 (s, 3H), 6.35 (t, J = 3.0 
Hz, 1H), 6.94 (s, 2H), 7.07 (s, 1H), 8.25 (s, 1H); 13C NMR (101 
MHz, CDCl3) δ 8.9, 9.0, 13.1, 24.3, 39.8, 53.1, 61.0, 107.6, 
110.3, 120.0, 123.5, 131.0, 132.2, 136.4, 145.3, 147.2, 173.0; 
HRMS (ESI): m/z calcd for C17H19N2O2 [M+H]+: 283.1441; found: 
283.1440. 
4-Methyl-4-propyl-1,2-dihydropyrrolo[1,2-a]pyrazin-3(4H)-
one (31): PtO2 (34 mg, 0.15 mmol) was added to a solution of 
20 (35 mg, 0.15 mmol) in MeOH (3 mL) and the reaction mixture 
was stirred under H2 atmosphere (1 atm) for 16 h. Then, the 
resulting suspension was filtered and the filtrate was 
concentrated under reduced pressure. The crude product was 
purified by flash column chromatography (silica gel; petroleum 
ether/EtOAc, 1:1) to yield 10 mg of 31 (35% yield) as colourless 
oil. Rf = 0.24 (petroleum ether/EtOAc; 1:1); 1H NMR (400 MHz, 
CDCl3) δ 0.82 (t, J = 7.2 Hz, 3H), 0.88 – 1.01 (m, 1H), 1.11 – 
1.23 (m, 1H), 1.72 (d, J = 4.5 Hz, 3H), 1.82 (ddd, J = 13.6, 10.3, 
4.3 Hz, 1H), 2.16 (ddd, J = 13.7, 12.1, 4.6 Hz, 1H), 4.52 – 4.63 
(m, 2H), 5.93 (d, J = 2.0 Hz, 1H), 6.25 (t, J = 3.2 Hz, 1H), 6.35 
(s, 1H), 6.69 (dd, J = 2.4, 1.8 Hz, 1H); 13C NMR (126 MHz, 
CDCl3) δ 14.0, 17.4, 26.4, 39.8, 43.7, 62.9, 102.8, 109.8, 115.9, 
122.1, 172.2; HRMS (ESI): m/z calcd for C11H17N2O [M+H]+: 
193.1335; found: 193.1328. 
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Synthesis of structurally diverse N-
substituted quaternary carbon containing 
small molecules from α,α-disubstituted 
propargyl amino esters,  
 
 
A reagent-based diversity-oriented synthesis approach to generate a small molecule library, starting from α, α -disubstituted 
propargyl amino esters, is reported. The strategy exploited the different reactivity of the alkyne, the amine and the ester moieties. The 
target library represents an attractive screening collection of small molecules with high scaffold diversity covering broad areas of both 
molecular shape space and bioactive space. 
 
 
